Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900730 | 0.93 | VNN1 (0.40) | VNN1NPC1RAB9ACA1CA2 | |
| SCHEMBL1899666 | 0.84 | CTSL (0.38) | VNN1DPP4SSTR4TACR3 | |
| SCHEMBL13254923 | 0.83 | SSTR4 (0.42) | VNN1DPP4NPC1RAB9ASSTR4 | |
| SCHEMBL14876759 | 0.80 | PGR (0.40) | OPRM1OPRD1OPRK1OPRL1PGR | |
| SCHEMBL14876760 | 0.80 | PGR (0.40) | OPRM1OPRD1OPRK1OPRL1PGR | |
| SCHEMBL2712662 | 0.79 | SSTR4 (0.53) | DPP4SSTR4HTTPOLBTACR3 | |
| SCHEMBL20556976 | 0.79 | HTT (0.50) | CA1CA2GAAHTTPGR | |
| SCHEMBL23908251 | 0.79 | CTSL (0.47) | NPC1RAB9AOPRM1OPRD1GAA | |
| SCHEMBL23224333 | 0.79 | ADRB2 (0.36) | VNN1GAAHTTPGR | |
| SCHEMBL361749 | 0.79 | AKT1 (0.40) | VNN1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802586-B1 | SUBSTITUTED IMIDAZOPYRAZINES AS AKT KINASE INHIBITORS | BAYER IP GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9260435-B2 | Substituted imidazopyrazines as Akt kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-16 | — | — | US | disclosed |
| US-9206185-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2694510-B1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-20150005309-A1 | SUBSTITUTED IMIDAZOPYRAZINES AS AKT KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2802586-A1 | SUBSTITUTED IMIDAZOPYRAZINES AS AKT KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2694510-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013104610-A1 | SUBSTITUTED IMIDAZOPYRAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012136776-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT1S1, AKT1 | VNN1 2872/4885DPP4 1956/4885NPC1 1662/4885 |
| US-20150005309-A1 | SUBSTITUTED IMIDAZOPYRAZINES AS AKT KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | VNN1 4518/4885DPP4 1612/4885NPC1 1244/4885 |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | PI4KA, PI4KB, PIK3CD | VNN1 3537/4885DPP4 699/4885NPC1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.